Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

计划入组 21 人 · 首次发布于 2019 年 2 月 26 日

Study of APVO436 in Patients With AML or MDS

计划入组 136 人 · 首次发布于 2018 年 8 月 27 日

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

计划入组 39 人 · 首次发布于 2024 年 10 月 9 日

APVO711

Aptevo Files Patent for Nectin-4 x PD-L1 Dual-Targeting Backbone to Expand Solid Tumor Strategy

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Advance Multispecific Cancer Immunotherapy Pipeline

Aptevo Advances APVO711: Novel Bispecific Antibody Combining PD-L1 Checkpoint Inhibition with CD40 Immune Activation